Date: 2012-04-18
Type of information: Development agreement
Compound: new insect silk based products
Company: Lonza (Switzerland) CSIRO (Australia)
Therapeutic area:
Type agreement: development
Action mechanism:
Disease:
Details: Australia’s Commonwealth Scientific and Industrial Research Organisation (CSIRO) and Lonza have entered a joint development agreement to advance and market exciting new insect silks for a broad range of medical and industrial applications.
Potential applications include composite fibers for the aviation and marine industries and medical applications including wound repair, drug delivery, and repairing and replacing human tissues such as membranes, ligaments, blood vessels and cartilage.
CSIRO is bringing scientific discovery, biomedical and materials science expertise to the partnership.
Lonza brings its biotechnology and life-science product and service expertise to the partnership and is already providing process development for the recombinant bee silk protein. CSIRO and Lonza are working closely to identify further commercial applications and partners for the new insect silk based products.
Financial terms:
Latest news:
